HealthQuill Treatment-resistant Depression
nasal spray
Drugs

Eli Lilly just spent $3.8 billion on psychedelics. Here’s why

HQ Team July 23, 2026: Eli Lilly, the pharma company behind weight-loss blockbusters Mounjaro and Zepbound recently agreed to buy AtaiBeckley, a psychedelic.

Read More
The US Food and Drug Administration has approved Johnson & Johnson’s nasal spray in adults who have had an inadequate response to at least two oral antidepressants for treating major depressive disorder.
Uncategorized

J&J’s nasal spray to treat major depressive disorder gets FDA nod

The US Food and Drug Administration has approved Johnson & Johnson’s nasal spray in adults who have had an inadequate response to at.

Read More
Drugs Health Pharma

Ketamine pill may revolutionize treatment for hard-to-treat depression

HQ Team October 25,  2024: A recent study indicates that a new slow-release ketamine pill could offer a promising alternative for individuals suffering.

Read More
Abbott Laboratories has initiated a clinical trial to evaluate the use of the company's deep brain stimulation system to manage treatment-resistant depression, a form of major depressive disorder.
Drugs Health Pharma

Abbott starts trial on deep brain stimulation for depressive disorder

Abbott Laboratories has initiated a clinical trial to evaluate the use of the company's deep brain stimulation system to manage treatment-resistant depression, a.

Read More